Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Pegaptanib Sodium Extension Study in Wet AMD
NCT00239928Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Primary completion
- Nov 2008
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of pegaptanib sodium in exudative macular degeneration, sponsored by Pfizer. Started Sep 2005; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00239928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239928.